Follicular lymphoma grade II, spleen
ICD-10 C82.17 is a billable code used to indicate a diagnosis of follicular lymphoma grade ii, spleen.
Follicular lymphoma grade II is a type of non-Hodgkin lymphoma characterized by the proliferation of follicle center (germinal center) B-cells. This malignancy typically presents in the lymph nodes but can also involve extranodal sites, including the spleen. The spleen is often affected in advanced stages of the disease, leading to splenomegaly. Patients may present with B-symptoms such as fever, night sweats, and weight loss, which indicate systemic involvement. The disease is classified into grades based on histological features, with grade II indicating a moderate proliferation of neoplastic cells. Diagnosis is confirmed through biopsy and immunophenotyping, revealing the presence of CD10, CD19, and CD20 markers. Treatment options vary based on the stage of the disease and may include watchful waiting, chemotherapy, immunotherapy, or targeted therapies. The prognosis for patients with follicular lymphoma grade II can vary, but it is generally considered an indolent form of lymphoma, with many patients living for years with effective management.
Detailed clinical notes including staging, treatment plans, and response to therapy.
Initial diagnosis, treatment planning, and follow-up of patients with follicular lymphoma.
Ensure accurate grading and staging are documented to support coding.
Histopathological reports detailing the grade and subtype of lymphoma.
Biopsy interpretation and reporting of lymphoid tissue.
Clear documentation of immunophenotyping results is crucial for accurate coding.
Used to monitor blood counts during treatment.
Document the reason for the CBC and any abnormalities noted.
Hematology specialists should ensure all lab results are linked to the diagnosis.
Grading in follicular lymphoma indicates the proliferation rate of the cancer cells, which can influence treatment decisions and prognosis. Grade II indicates a moderate proliferation rate, which may require more aggressive treatment compared to grade I.
